Testing effectiveness (Phase 2)Study completedNCT00550537
What this trial is testing
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Who this might be right for
Lung Cancer
Vanderbilt-Ingram Cancer Center 116